{"analyses":[{"ciLowerLimit":"0.640","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.038","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.815"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.15","upperLimit":"24.21","value":"19.84"},{"groupId":"OG001","lowerLimit":"11.79","upperLimit":"18.73","value":"13.73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"description":"LFS is defined as the time from randomization to ≥ 20% blasts in bone marrow/peripheral blood (per WHO 2016 classification) or diagnosis of extramedullary acute leukemia, or death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"MEDIAN","populationDescription":"FAS comprised of all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"up to approx. 52 months","title":"Leukemia-free Survival (LFS)","type":"SECONDARY","unitOfMeasure":"Months"}